Small Stocks, Big Money

In this exclusive interview, Bruce Ogilvie, Executive Chairman of Alliance Entertainment (NASDAQ: AENT), outlines the company’s strategy to drive sustainable earnings growth across physical media, collectibles, and exclusive licensed content. Alliance Entertainment sits at the center of the global entertainment and collectibles ecosystem, distributing over 340,000 SKUs across vinyl, film, video ga...

In this exclusive interview, David Young, PhD, President of Research & Development and Founder of Processa Pharmaceuticals (Nasdaq: PCSA), breaks down the latest Phase 2 clinical progress for the company’s lead oncology program targeting advanced breast cancer.🔬 Key Topics We Covered:• Positive preliminary Phase 2 data from the oral combination therapy PCS6422 + capecitabine• Evidence showing...

In this exclusive interview, E. Will Gray II, Chairman, CEO, and Interim CFO of New Era Energy & Digital (Nasdaq: NUAI), breaks down the company’s strategy to become a critical player in AI data center infrastructure and power generation. New Era Energy & Digital is developing large scale, powered data center sites in the Permian Basin, leveraging behind the meter natural gas, future nucle...

In our in-depth interview, NioCorp (Nasdaq: NB) CEO Mark Smith discusses the rapidly evolving landscape for U.S. critical minerals and the company’s progress toward construction of its Elk Creek Project in Nebraska. Investors will gain insight into supply chain pressures, heavy rare earth export dynamics, and the rising strategic importance of niobium, scandium, and rare earth elements in defense...

📌 In our exclusive interview, Nova Minerals (Nasdaq: NVA) CEO Chris Gerteisen breaks down the company’s rapid transformation into a U.S. critical minerals and gold development leader. With a $43.4 million Defense Production Act award from the U.S. Department of War, Nova is advancing toward military-grade antimony production by 2026/27 — positioning itself as the first fully integrated domestic s...

In this exclusive interview, BullFrog AI (Nasdaq: BFRG) CEO Vin Singh discusses how the company’s proprietary bfLEAP™ AI platform and BullFrog Data Networks™ are redefining the economics of drug discovery and development.💡 Key Highlights from the Interview:• Exclusive Data Access: Collaborations with the Lieber Institute for Brain Development and J. Craig Venter Institute provide unmatched datase...

Jackpot Digital (OTCQB: JPOTF | TSXV: JJ) CEO Jake Kalpakian discusses how the company’s flagship Jackpot Blitz® platform is redefining casino poker economics through automation, recurring revenue, and global expansion.💡 Jackpot Digital represents an emerging opportunity at the intersection of technology, automation, and gaming, offering exposure to a rapidly growing segment of the global casino...

🚀 Connect Biopharma (Nasdaq: CNTB) is advancing rademikibart, a next-generation biologic designed to redefine how asthma and COPD are treated — tackling both chronic and acute exacerbations where no biologic currently competes. In this exclusive RedChip Money Report interview, CEO Dr. Barry Quart discusses:✅ How rademikibart targets the IL-4Rα pathway — the same as Dupixent — but with faster ons...

📊 FatPipe Networks (Nasdaq: FATN) — a pioneer in mission-critical networking and cybersecurity — is driving strong profitability and growth in the multi-billion-dollar SD-WAN and SASE markets. In this exclusive interview, Ragula Bhaskar, PhD, Co-Founder and CEO of FatPipe, discusses:✅ The company’s patented technology and 13 foundational networking patents✅ FatPipe’s 90%+ gross margins and subs...

💡 60 Degrees Pharmaceuticals (Nasdaq: SXTP) CEO Geoff Dow discusses the company’s mission to tackle infectious diseases with unmet medical needs — and how its FDA-approved malaria drug ARAKODA® (tafenoquine) could soon transform treatment for babesiosis, a growing tick-borne disease with no approved therapies.🚀 Key Highlights:• FDA Breakthrough Therapy Designation request submitted for tafenoqui...

🔋 Bimergen Energy (OTCQB: BESS) is emerging as a major player in the booming U.S. battery energy storage sector—and CFO Bob Brilon shares how the company is executing on a 2.0 GW pipeline backed by $250 million in equity commitments. With 2GW of BESS assets and a capital-efficient model designed to avoid shareholder dilution, Bimergen is positioned to become a cornerstone in the next generation o...

Mark White, CEO of Nexalin Technology (Nasdaq: NXL), joins us to discuss how Nexalin aims to simplify and make mental health care more accessible with its at-home “Halo” headset and a digital, physician-monitored model. We cover the latest peer-reviewed study results referenced by the company, the plan for U.S. and international pathways, and what investors should watch next.🎯 What you’ll learn•...

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefiningoncology drug development through artificial intelligence. Its proprietary RADR® platform leveragesover 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patienttargeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%,respective...

Foremost Clean Energy (Nasdaq: FMST) is a rapidly growing North American uranium exploration holding an option to earn up to a 70% interest in 10 underexplored properties from Denison Mines. The portfolio spans over 330,000 acres within a prospective area of the Athabasca Basin surrounded by high-grade deposits. Driven by the resurgent Nuclear Renaissance, Foremost is dedicated to realizing the fu...

Phoenix Motor (OTC: PEVMD) is a pioneer and emerging leader in the electric vehicle (“EV”) industry, designing, building, and integrating electric drive systems and manufacturing heavy-duty transit buses and medium- and light- duty commercial EVs. Phoenix operates two primary brands, PhoenixEV, focused on commercial products including heavy and medium duty EVs (transit buses, shuttle buses, school...

60 Degrees Pharmaceuticals (Nasdaq: SXTP) is a growth-oriented biotechnology company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. 60P has successfully achieved regulatory approval of ARAKODA® (tafenoquine), a malaria preventative treatment that has been on the ma...

Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies through its proprietary bispecific antibody platforms, ADAPTIR® and ADAPTIR-FLEX®. The company is advancing a diverse pipeline that includes both clinical and preclinical candidates designed to harness the immune system to target hematologic and solid tumors with...

Calidi Biotherapeutics (NYSE American: CLDI) is a clinical-stage immuno-oncology company with proprietary technology designed to arm the immune system to fight cancer. Calidi’s novel stem cell-based platforms are utilizing potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s...

Lantern Pharma Inc. (Nasdaq: LTRN) is a clinical-stage biopharmaceutical company redefining oncology drug development through artificial intelligence. Its proprietary RADR® platform leverages over 200 billion oncology-specific data points to rapidly identify drug candidates, optimize patient targeting, and de-risk clinical trials—cutting early development time and cost by up to 70% and 80%, respec...

Atossa Therapeutics, Inc. (Nasdaq: ATOS) is a clinical-stage biopharmaceutical company advancing (Z)-endoxifen, a next-generation selective estrogen receptor modulator (SERM) with best-in-class potential across the breast cancer treatment spectrum. The company is strategically prioritizing metastatic breast cancer, where (Z)-endoxifen has shown encouraging clinical activity, favorable tolerability...

Processa Pharmaceuticals (Nasdaq: PCSA) is a clinical-stage pharmaceutical company focused on developing the Next Generation Cancer (NGC) drugs with improved safety and efficacy. Processa's NGC drugs are modifications of existing FDA-approved oncology therapies, resulting in an alteration of the metabolism and/or distribution of these drugs while maintaining the existing mechanisms of killing...

Greenwich LifeSciences (Nasdaq: GLSI) is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu (human epidermal growth factor receptor 2) protein, a cell surface receptor protein that is expressed in a variety o...

Fathom Holdings Inc. (Nasdaq: FTHM) is a technology-driven real estate services platform revolutionizing the traditional brokerage model. Through its innovative flat-fee commission structure, proprietary technology, and integrated offerings—spanning residential brokerage, mortgage, title, and SaaS—Fathom enables agents to maximize their earnings while delivering superior scalability and efficiency...

ASP Isotopes is an advanced materials company dedicated to the development of technology and processes to produce isotopes for use in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process, to produce and commercialize highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy...

Enlivex (Nasdaq: ENLV) is a clinical stage macrophage reprogramming immunotherapy company developing AllocetraTM, a universal, off-the-shelf cell therapy designed to reprogram macrophages, which are primary immune cells, into their homeostatic state. Osteoarthritis and many other diseases reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significant...